var data={"title":"Crimean-Congo hemorrhagic fever","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Crimean-Congo hemorrhagic fever</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/contributors\" class=\"contributor contributor_credentials\">Hakan Leblebicioglu, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/contributors\" class=\"contributor contributor_credentials\">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 13, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H538750190\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Crimean-Congo hemorrhagic fever (CCHF) is a zoonotic disease transmitted by ticks and characterized by fever and hemorrhage [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/1,2\" class=\"abstract_t\">1,2</a>]. It was first described in Soviet soldiers in the Crimea in 1944 and was named Crimean fever. In 1956, the virus was isolated from a child with similar symptoms and was named Congo virus [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/3\" class=\"abstract_t\">3</a>]. The causative agent of both illnesses was shown to be the same virus, which was subsequently termed Crimean-Congo hemorrhagic fever virus (CCHFV) [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/4\" class=\"abstract_t\">4</a>]. CCHF infects a range of animals; humans are the only known host that develops disease.</p><p class=\"headingAnchor\" id=\"H538750202\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Crimean-Congo hemorrhagic fever (CCHF) is an emerging infectious disease given the expanding distribution of its main vector, ticks of the genus <em>Hyalomma</em>. Each year, more than 1000 human cases are reported from southeastern Europe and western Asia [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/5-7\" class=\"abstract_t\">5-7</a>]. The primary means of transmission to humans is via tick bites.</p><p class=\"headingAnchor\" id=\"H10384496\"><span class=\"h2\">Geography and season</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CCHF is endemic in parts of Africa, the Middle East, Asia, and southeastern Europe [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/5,6,8\" class=\"abstract_t\">5,6,8</a>]. CCHF virus has been observed in over 30 countries, including in Africa (Democratic Republic of Congo, South Africa, Nigeria, Senegal, Uganda, Tanzania, Mauritania, Kenya), Asia (Pakistan, Afghanistan, Tajikistan, Uzbekistan, Kazakhstan, China), the Middle East (Iran, Iraq, United Arab Emirates, Saudi Arabia, Oman), and southeastern Europe (the Russian Federation, Bulgaria, Albania, Kosovo, Turkey, Greece, and Spain) (<a href=\"image.htm?imageKey=ID%2F104847\" class=\"graphic graphic_figure graphicRef104847 \">figure 1</a>) [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/5,8-10\" class=\"abstract_t\">5,8-10</a>]. Emergence of CCHF in India was reported in 2011 [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/11\" class=\"abstract_t\">11</a>], and CCHF in Spain was first reported in 2016 [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/8,12\" class=\"abstract_t\">8,12</a>]. Between 1998 and 2013, CCHF occurred most frequently in Turkey, Russia, Iran, Pakistan, and Afghanistan [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/7,13\" class=\"abstract_t\">7,13</a>].</p><p>In the Northern Hemisphere, transmission of CCHF virus (CCHFV) is common between May and September, with a peak incidence in June and July [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/14\" class=\"abstract_t\">14</a>]. In Pakistan, CCHF has biannual peaks between March and May and between August and October [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/15\" class=\"abstract_t\">15</a>]. In Turkey, there is peak transmission in early summer months and a strong association with living at altitude greater than 836.5 m [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/16\" class=\"abstract_t\">16</a>]. Seasonal transmission at moderate altitudes, typically around 1000 m, has been reported in other studies, presumably reflecting optimum conditions for tick populations [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/17,18\" class=\"abstract_t\">17,18</a>].</p><p class=\"headingAnchor\" id=\"H538750208\"><span class=\"h3\">Ticks</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CCHFV is primarily transmitted via hard-bodied <em>Hyalomma </em>ticks of the family Ixodes<em>,</em> particularly <em>Hyalomma marginatum</em> [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/19\" class=\"abstract_t\">19</a>]. The geography of CCHF infection reflects the distribution of <em>Hyalomma</em> ticks, which have a northern geographic limit of 48&deg; north latitude [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/20\" class=\"abstract_t\">20</a>]. CCHFV has also been isolated from <em>Rhipicephalus, Boophilus, </em>and <em>Dermacentor</em> spp, which may also transmit the virus [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/21\" class=\"abstract_t\">21</a>].</p><p>The most common viral reservoirs are domestic livestock (sheep, goat, cattle, and pig), which are infected by adult ticks. Larvae and nymphs tend to feed on rodents, hares, hedgehogs, and ground-dwelling birds, which serve as amplifying hosts for the virus [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/2\" class=\"abstract_t\">2</a>]. <em>Hyalomma </em>ticks have a two-year life cycle (<a href=\"image.htm?imageKey=ID%2F104846\" class=\"graphic graphic_figure graphicRef104846 \">figure 2</a>), and blood meals are required for development at each life cycle stage. Ticks can remain attached for 2 to 13 days; after completion of feeding, the ticks detach from the host and begin to search for new hosts. The virus begins to multiply within 36 hours of attachment [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/22\" class=\"abstract_t\">22</a>]; it does not have the ability to survive outside the host but may persist in infected body fluids such as blood, stool, or vomit.</p><p>Ticks survive most readily in relatively warm, dry habitats. Tick density increases markedly following a preceding mild winter and in the setting of diminished rainfall; these conditions are associated with increased numbers of human CCHF cases [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/23,24\" class=\"abstract_t\">23,24</a>].</p><p>Changing tick habitats and elimination of usual host animals may lead to an increase in the spread of tickborne disease [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/25\" class=\"abstract_t\">25</a>]. Environmental factors associated with CCHF infection include livestock grazing at the edge of forests and presence of scrub and herbaceous vegetation [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/26,27\" class=\"abstract_t\">26,27</a>]. (See <a href=\"#H10384935\" class=\"local\">'Disease emergence'</a> below.)</p><p class=\"headingAnchor\" id=\"H10384935\"><span class=\"h3\">Disease emergence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The incidence of CCHF appears to be increasing. Possible causes of CCHF outbreaks include changing agricultural practices, climate change [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/28-30\" class=\"abstract_t\">28-30</a>], movement of domestic animals [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/30-32\" class=\"abstract_t\">30-32</a>], migrating birds [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/33,34\" class=\"abstract_t\">33,34</a>], increasing numbers of susceptible animals, and increasing tick populations [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/5,9\" class=\"abstract_t\">5,9</a>]. Changing agriculture practices such as deforestation and irrigation projects may be associated with increased contact with vectors [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/21,31\" class=\"abstract_t\">21,31</a>]. Conversely, reducing agricultural activities may be associated with increases in wildlife and numbers of ticks in a particular area; subsequent utilization of such areas for farming may be associated with CCHF outbreaks [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/3,35\" class=\"abstract_t\">3,35</a>]. Increased diagnostic awareness may also play a role in the apparent increased incidence [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/11\" class=\"abstract_t\">11</a>].</p><p class=\"headingAnchor\" id=\"H538750214\"><span class=\"h2\">Transmission</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CCHF is transmitted via ticks, direct contact with blood or other bodily fluids of infected animals, nosocomial transmission, and vertical transmission.</p><p>CCHF is most commonly transmitted via tick bites or crushing ticks with bare fingers. Ticks can attach to all sites of the human body, including the trunk, extremities, and head and neck [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/36\" class=\"abstract_t\">36</a>]; <em>H. marginatum</em> commonly attaches to the trunk [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/37\" class=\"abstract_t\">37</a>].</p><p>Transmission can also occur via direct contact with blood or other bodily fluids of livestock; abattoir workers and farmers are at increased risk for infection [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/2,38-40\" class=\"abstract_t\">2,38-40</a>]. In a large epidemiologic study including more than 1800 cases of CCHF, 69 percent of patients reported a history of tick bite or tick contact, 62 percent reported close contact with animals, and 10 percent had history of direct contact with animal body fluids or tissue [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/14\" class=\"abstract_t\">14</a>].</p><p>The risk of community-based transmission to close contacts and relatives of patients with CCHF is low [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/41-43\" class=\"abstract_t\">41-43</a>]. Relatives and caregivers should avoid direct contact with infected patients and their <span class=\"nowrap\">blood/bodily</span> fluids, wear gloves and protective clothes, and wash hands regularly. Personal items such as razors or toothbrushes should not be shared.</p><p>Nosocomial transmission of CCHFV has been described [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/44-46\" class=\"abstract_t\">44-46</a>]. The risk is highest during later stages of disease, which are associated with higher viral loads as well as diarrhea, vomiting, and hemorrhage [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/47\" class=\"abstract_t\">47</a>]. Direct contact with blood and body fluids, needle-stick injuries, and splash exposures are common causes of nosocomial transmission [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/47-50\" class=\"abstract_t\">47-50</a>]. Healthcare personnel are also at risk of infection during aerosol-generating procedures [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/51,52\" class=\"abstract_t\">51,52</a>]. Transmission between patients sharing the same hospital room has occurred, likely due to contact with infected blood or body fluids [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/53\" class=\"abstract_t\">53</a>]. (See <a href=\"#H10394923\" class=\"local\">'Infection control'</a> below.)</p><p>Vertical (mother-to-child) transmission of CCHFV has been described; in such cases, fetal prognosis may be guarded [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/54,55\" class=\"abstract_t\">54,55</a>]. Thus far, breastfeeding has not been associated with CCHFV transmission [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/56\" class=\"abstract_t\">56</a>]. The role of sexual transmission is uncertain [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/57,58\" class=\"abstract_t\">57,58</a>]; CCHF with epididymoorchitis has been described [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/59\" class=\"abstract_t\">59</a>] as has detection of CCHFV in urine [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/60,61\" class=\"abstract_t\">60,61</a>].</p><p>The risk of laboratory exposure to CCHFV while processing blood samples is low if routine laboratory procedures are followed [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/47\" class=\"abstract_t\">47</a>].</p><p class=\"headingAnchor\" id=\"H538750220\"><span class=\"h2\">Risk groups</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Individuals at risk for CCHFV infection include agricultural workers, individuals in rural areas engaged in animal husbandry, abattoir workers, veterinarians, leather factory workers in areas with high tick density, campers and hikers, hunters, soldiers, healthcare workers, and travelers to endemic areas (particularly in the setting of exposure to farming and slaughtering) [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/2,38,52,62-68\" class=\"abstract_t\">2,38,52,62-68</a>].</p><p>In high-risk populations, the seroprevalence of CCHFV infection is 10 to 14 percent [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/69-71\" class=\"abstract_t\">69-71</a>]. Independent risk factors for seropositivity include history of tick bite, manually removing ticks from animals, animal husbandry or farming, age &gt;60 years, and residence in a rural area [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/69-72\" class=\"abstract_t\">69-72</a>]. Data are insufficient regarding the risk of CCHFV infection in immunocompromised hosts.</p><p class=\"headingAnchor\" id=\"H8904604\"><span class=\"h1\">VIROLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Crimean-Congo hemorrhagic fever virus (CCHFV) is a member of the <em>Nairovirus</em> genus within the family Bunyaviridae, which contains negative-stranded, enveloped RNA viruses. The genome of CCHFV has three segments, which are small (S), medium (M), and large (L). Based on the CCHFV S-segment sequences, CCHFV strains have seven clades in different geographical locations [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/9,73-77\" class=\"abstract_t\">9,73-77</a>]. All Balkan strains are clustered in the same branch [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/78\" class=\"abstract_t\">78</a>], and they are closely related to Turkish and southwestern Russian strains [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/9\" class=\"abstract_t\">9</a>]. Detection of several viral variants and differences in clade distribution have been demonstrated over time [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/79\" class=\"abstract_t\">79</a>], and cross-border movements of livestock may have contributed to the insertion of new clades into countries and spread of the disease [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/80\" class=\"abstract_t\">80</a>]. Wild birds have also been shown to have the capacity to carry ticks containing CCHFV to different geographic areas [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/33\" class=\"abstract_t\">33</a>].</p><p class=\"headingAnchor\" id=\"H538750256\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The spectrum of clinical manifestations ranges from subclinical illness (88 percent) to acute infection with hemorrhage and multiorgan failure [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/14,69\" class=\"abstract_t\">14,69</a>]. The incubation period ranges from 1 to 13 days; it correlates with viral load and the type of transmission. The incubation period following tick bite is typically 1 to 3 days; the incubation period following contact with blood and body fluids is typically 3 to 7 days [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/81,82\" class=\"abstract_t\">81,82</a>]. Relatively short incubation periods have been described in cases due to nosocomial infection during later stages of disease, which are associated with high viral loads as well as diarrhea, vomiting, and hemorrhage [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/47,83\" class=\"abstract_t\">47,83</a>].</p><p>Clinical manifestations of Crimean-Congo hemorrhagic fever (CCHF) include sudden onset of fever, headache, malaise, myalgia, sore throat, dizziness, conjunctivitis, photophobia, abdominal pain, nausea, and vomiting [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/1,14,84,85\" class=\"abstract_t\">1,14,84,85</a>]. One case series including more than 1600 patients with CCHF reported frequency of clinical manifestations as follows: fever (89 percent), headache (68 percent), myalgia (70 percent), fatigue (92 percent), nausea (65 percent), vomiting (43 percent), diarrhea (25 percent), and hemorrhage (23 percent) [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/14\" class=\"abstract_t\">14</a>]. Rales are generally associated with pulmonary hemorrhage [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/86\" class=\"abstract_t\">86</a>]. Ocular findings include subconjunctival and retinal hemorrhage, which may occur in the absence of visual complaints [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/87\" class=\"abstract_t\">87</a>]. Other clinical findings include tachycardia, hepatomegaly, lymphadenopathy, and confusion.</p><p>The initial period of nonspecific symptoms generally lasts up to seven days and is followed by either recovery or progression to severe disease [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/88\" class=\"abstract_t\">88</a>]. The convalescence period in recovering patients generally lasts up to four weeks with no long-term sequelae.</p><p>In severe cases, hemorrhagic manifestations are observed; these include petechiae (<a href=\"image.htm?imageKey=ID%2F104939\" class=\"graphic graphic_picture graphicRef104939 \">picture 1</a>), ecchymoses (<a href=\"image.htm?imageKey=ID%2F104940\" class=\"graphic graphic_picture graphicRef104940 \">picture 2</a> and <a href=\"image.htm?imageKey=ID%2F104941\" class=\"graphic graphic_picture graphicRef104941 \">picture 3</a>), epistaxis, and gum bleeding (<a href=\"image.htm?imageKey=ID%2F104942\" class=\"graphic graphic_picture graphicRef104942 \">picture 4</a>). Pulmonary hemorrhage, intraabdominal bleeding, hematuria, melena, and vaginal bleeding (menorrhagia or early menstrual bleeding) can also occur. Severe disease is thought to be due to an exaggerated proinflammatory cytokine response (&quot;cytokine storm&quot;), causing endothelial cell activation and increased vascular permeability, resulting in hypotension, shock, multiple organ failure, and death [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/89-93\" class=\"abstract_t\">89-93</a>].</p><p>Laboratory findings may include thrombocytopenia, leukopenia, hyperbilirubinemia with elevated transaminases, and prolongation of international normalized ratio, prothrombin time, and activated partial thromboplastin time [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/14,94\" class=\"abstract_t\">14,94</a>]. Anemia is observed in some cases. In the setting of multiorgan failure, elevated blood urea nitrogen, creatinine, and creatine phosphokinase may be present. Patients with disseminated intravascular coagulation have decreased fibrinogen levels and increased fibrin-degradation products [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/45\" class=\"abstract_t\">45</a>].</p><p class=\"headingAnchor\" id=\"H538750262\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of Crimean-Congo hemorrhagic fever (CCHF) should be suspected in patients presenting with fever and bleeding who have relevant geographic and epidemiologic risk factors (including exposure to an endemic region within the previous two weeks in addition to known tick bite <span class=\"nowrap\">and/or</span> contact with animal tissue or body fluids). (See <a href=\"#H538750202\" class=\"local\">'Epidemiology'</a> above.)</p><p>Diagnostic tools include detection of CCHF virus (CCHFV) RNA by reverse-transcriptase polymerase chain reaction (RT-PCR) and specific immunoglobulin (Ig)M and IgG by enzyme-linked immunosorbent assay (ELISA). In endemic areas, diagnostic testing may be limited to reference laboratories. If available, RT-PCR is preferred; this test allows rapid and accurate diagnosis of CCHFV with high sensitivity and specificity [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/95-97\" class=\"abstract_t\">95-97</a>]. Specific IgM and IgG antibodies are detectable five days from the onset of symptoms [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/98\" class=\"abstract_t\">98</a>], and IgG antibodies can remain detectable for at least five years [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/2\" class=\"abstract_t\">2</a>]. Specific IgM positivity in a single sample indicates current infection, and seroconversion or fourfold rise of CCHFV IgG antibody levels in paired sera confirm recent or current infection [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/2\" class=\"abstract_t\">2</a>].</p><p>CCHFV can be cultured in cell culture; this requires biosafety level 4 laboratories and is only used for research purposes.</p><p class=\"headingAnchor\" id=\"H538750274\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis depends on the geographic region and includes:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other viral hemorrhagic fevers &ndash; Other viruses capable of causing hemorrhagic fever include dengue, Ebola, Marburg, Lassa, and yellow fever. These illnesses can all cause severe multiorgan system illness accompanied by hemorrhage. The diseases may be distinguished based on relevant epidemiologic exposure and polymerase chain reaction or serologic testing. (See <a href=\"topic.htm?path=dengue-virus-infection-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Dengue virus infection: Clinical manifestations and diagnosis&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-ebola-virus-disease\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of Ebola virus disease&quot;</a> and <a href=\"topic.htm?path=marburg-virus\" class=\"medical medical_review\">&quot;Marburg virus&quot;</a> and <a href=\"topic.htm?path=yellow-fever\" class=\"medical medical_review\">&quot;Yellow fever&quot;</a> and <a href=\"topic.htm?path=lassa-fever\" class=\"medical medical_review\">&quot;Lassa fever&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Malaria &ndash; Clinical manifestations of malaria include fever, chills, malaise, fatigue, diaphoresis, headache, cough, anorexia, nausea, vomiting, abdominal pain, diarrhea, arthralgias, and myalgias. The diagnosis is established by microscopy or rapid diagnostic testing. (See <a href=\"topic.htm?path=clinical-manifestations-of-malaria-in-nonpregnant-adults-and-children\" class=\"medical medical_review\">&quot;Clinical manifestations of malaria in nonpregnant adults and children&quot;</a> and <a href=\"topic.htm?path=diagnosis-of-malaria\" class=\"medical medical_review\">&quot;Diagnosis of malaria&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Rickettsial infection &ndash; Certain rickettsial infections (such as scrub typhus, African tick bite fever) may begin insidiously or abruptly; most patients develop high fever, headache, and myalgias, and an eschar or rash may develop in a subset of patients. The diagnosis is confirmed via serology. (See <a href=\"topic.htm?path=scrub-typhus-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Scrub typhus: Clinical features and diagnosis&quot;</a> and <a href=\"topic.htm?path=other-spotted-fever-group-rickettsial-infections\" class=\"medical medical_review\">&quot;Other spotted fever group rickettsial infections&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Q fever &ndash; Acute Q fever most commonly presents as a flu-like illness, pneumonia, or hepatitis, typically in association with animal exposure. The diagnosis is established via serology. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-q-fever\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of Q fever&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Brucellosis &ndash; Acute brucellosis usually consists of fever, night sweats, arthralgias, myalgias, low back pain, and weight loss as well as weakness, fatigue, malaise, headache, dizziness, depression, and anorexia; it is transmitted via unpasteurized dairy products from infected animals. The diagnosis is established via culture or serology. (See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-brucellosis\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and treatment of brucellosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Leptospirosis &ndash; Leptospirosis presents with the abrupt onset of fever, rigors, myalgias, and headache; conjunctival suffusion is an important sign. The diagnosis is established by serologic testing. (See <a href=\"topic.htm?path=epidemiology-microbiology-clinical-manifestations-and-diagnosis-of-leptospirosis\" class=\"medical medical_review\">&quot;Epidemiology, microbiology, clinical manifestations, and diagnosis of leptospirosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Relapsing fever &ndash; Clinical manifestations of relapsing fever include acute febrile episodes punctuated by an intervening afebrile period; headache, neck stiffness, arthralgia, myalgia, and nausea may accompany the fever. The diagnosis is established by blood smear. (See <a href=\"topic.htm?path=clinical-features-diagnosis-and-management-of-relapsing-fever\" class=\"medical medical_review\">&quot;Clinical features, diagnosis, and management of relapsing fever&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Viral hepatitis &ndash; Clinical manifestations of viral hepatitis include jaundice, hepatomegaly, and elevated aminotransferases; the diagnosis is established via serology. (See <a href=\"topic.htm?path=hepatitis-a-virus-infection-in-adults-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Hepatitis A virus infection in adults: Epidemiology, clinical manifestations, and diagnosis&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-natural-history-of-hepatitis-b-virus-infection\" class=\"medical medical_review\">&quot;Clinical manifestations and natural history of hepatitis B virus infection&quot;</a> and <a href=\"topic.htm?path=hepatitis-b-virus-screening-and-diagnosis\" class=\"medical medical_review\">&quot;Hepatitis B virus: Screening and diagnosis&quot;</a> and <a href=\"topic.htm?path=diagnosis-and-evaluation-of-chronic-hepatitis-c-virus-infection\" class=\"medical medical_review\">&quot;Diagnosis and evaluation of chronic hepatitis C virus infection&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Meningococcemia &ndash; Clinical manifestations of meningococcemia include fever, nausea, vomiting, headache, myalgias, and petechial rash. The diagnosis consists of isolation of <em>Neisseria meningitidis</em> by culture from a usually sterile body fluid, such as blood or cerebrospinal fluid. (See <a href=\"topic.htm?path=clinical-manifestations-of-meningococcal-infection\" class=\"medical medical_review\">&quot;Clinical manifestations of meningococcal infection&quot;</a> and <a href=\"topic.htm?path=diagnosis-of-meningococcal-infection\" class=\"medical medical_review\">&quot;Diagnosis of meningococcal infection&quot;</a>.)</p><p/><p>In addition, noninfectious entities in the differential diagnosis include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Idiopathic thrombocytopenic purpura (ITP) &ndash; Clinical manifestations of ITP include bleeding (petechiae, epistaxis, purpura, <span class=\"nowrap\">and/or</span> severe hemorrhage) and thrombocytopenia. The diagnosis is made following elimination of other potential causes of thrombocytopenia. (See <a href=\"topic.htm?path=immune-thrombocytopenia-itp-in-adults-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Immune thrombocytopenia (ITP) in adults: Clinical manifestations and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acute leukemia &ndash; Clinical manifestations of acute leukemia may include signs and symptoms of anemia (eg, shortness of breath, dyspnea on exertion, pallor), excess bleeding or bruising, and infection. The diagnosis is established via bone marrow biopsy. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-acute-myeloid-leukemia\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H538750280\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no proven antiviral treatment for Crimean-Congo hemorrhagic fever (CCHF) infection. <a href=\"topic.htm?path=ribavirin-drug-information\" class=\"drug drug_general\">Ribavirin</a> has been studied in vitro, in animal models, and in some patients [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/99-102\" class=\"abstract_t\">99-102</a>]; it has not been shown to reduce viral load or mortality in humans [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/84,103-108\" class=\"abstract_t\">84,103-108</a>], and its clinical efficacy is controversial [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/84,105,109-111\" class=\"abstract_t\">84,105,109-111</a>]. In addition, most of the studies evaluating the effectiveness of ribavirin are limited by methodology flaws [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/112\" class=\"abstract_t\">112</a>]; further study is needed.</p><p>Management of CCHF consists of supportive care; in severe cases, blood product replacement is warranted [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/113\" class=\"abstract_t\">113</a>]. Patients with CCHF should be managed in a healthcare center with appropriate facilities for diagnosis, treatment, and prevention of disease, including isolation precautions. (See <a href=\"#H10394923\" class=\"local\">'Infection control'</a> below.)</p><p>Data are insufficient to support routine use of steroids, intravenous immunoglobulin, or plasma exchange [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/113-116\" class=\"abstract_t\">113-116</a>]. Use of hyperimmunoglobulin (which is prepared from the plasma of donors with antibody against CCHF) requires further study. Hyperimmunoglobulin can decrease viral load via direct neutralization, although viral strain variability may be an important determination in the use of this therapy [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/117\" class=\"abstract_t\">117</a>].</p><p class=\"headingAnchor\" id=\"H538750286\"><span class=\"h2\">Supportive care</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Supportive treatment is essential for management of CCHF [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/113\" class=\"abstract_t\">113</a>]. Careful attention should be paid to fluid balance and electrolytes. Mechanical ventilation, hemodialysis, vasopressor, and inotropic agents may be needed. <a href=\"topic.htm?path=acetaminophen-paracetamol-drug-information\" class=\"drug drug_general\">Acetaminophen</a> may be used for fever and pain management; <a href=\"topic.htm?path=ibuprofen-drug-information\" class=\"drug drug_general\">ibuprofen</a> and <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> should be avoided as these agents can adversely affect normal clotting.</p><p>Platelet transfusion is warranted to maintain platelet count <span class=\"nowrap\">&gt;50,000/mm<sup>3</sup></span> in the setting of bleeding and for patients with platelet count <span class=\"nowrap\">&lt;20,000/mm<sup>3</sup></span> in the absence of bleeding [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/118\" class=\"abstract_t\">118</a>]. The need for blood transfusion should be assessed based on the hemoglobin level as well as the general clinical status. Unnecessary interventional procedures should be avoided to minimize risk of bleeding.</p><p>In nonsevere cases, symptoms usually resolve in 7 to 10 days. In the absence of bleeding, transaminases and platelet counts tend to return to normal levels after 5 to 10 days.</p><p class=\"headingAnchor\" id=\"H10394923\"><span class=\"h2\">Infection control</span></p><p class=\"headingAnchor\" id=\"H10395304\"><span class=\"h3\">Precautions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infection control precautions (including standard, contact, and droplet precautions) should be implemented to prevent nosocomial transmission of CCHF [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/9,119\" class=\"abstract_t\">9,119</a>]. Patients with suspected or confirmed CCHF should be treated in isolation rooms [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/120\" class=\"abstract_t\">120</a>]; if this is not possible, cohorting of patients is appropriate. The number of healthcare personnel entering patient rooms should be minimized. (See <a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection\" class=\"medical medical_review\">&quot;Infection prevention: Precautions for preventing transmission of infection&quot;</a>.)</p><p>Healthcare worker training about CCHF transmission, exposure prevention, hand hygiene, and use of personal protective equipment is essential [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/119,121\" class=\"abstract_t\">119,121</a>]. Contact precautions include appropriate personal protective equipment (an impervious gown, gloves, mask, and <span class=\"nowrap\">eye/face</span> protection) [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/119\" class=\"abstract_t\">119</a>]. Respiratory protection (N95 mask or FFP3 respirator) is required during aerosol-generating procedures. Shoe covers are warranted when there is significant environmental contamination. It is essential to remove and dispose of personal protective equipment safely when leaving patient rooms [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/52,120,122\" class=\"abstract_t\">52,120,122</a>].</p><p>Using &quot;safe-sharps&quot; systems help prevent needle-stick injuries. Principles of safe phlebotomy should be adhered to, and needles must not be recapped. All sharps and needles should be disposed of in hard containers and at the point of use.</p><p>Precautions may be discontinued for patients with no signs and symptoms of disease for at least three days, with a platelet count <span class=\"nowrap\">&gt;50,000/mm<sup>3</sup></span> and normal coagulation tests (international normalized ratio, prothrombin time, and activated partial thromboplastin time). If possible, a negative blood polymerase chain reaction for viral hemorrhagic fever should also be documented [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/123,124\" class=\"abstract_t\">123,124</a>].</p><p class=\"headingAnchor\" id=\"H10395078\"><span class=\"h3\">Postexposure management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The exposed individual should undergo a two-week period of monitoring for symptoms or signs of CCHF, including daily temperature measurement and weekly assessment of complete blood count measurement; no quarantine is required [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/81,125\" class=\"abstract_t\">81,125</a>]. Development of a febrile illness during the monitoring period should prompt diagnostic testing. (See <a href=\"#H538750262\" class=\"local\">'Diagnosis'</a> above.)</p><p>The role of <a href=\"topic.htm?path=ribavirin-drug-information\" class=\"drug drug_general\">ribavirin</a> for prevention of clinical illness when given as postexposure prophylaxis is uncertain [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/48,50,52,126,127\" class=\"abstract_t\">48,50,52,126,127</a>]; further study is needed.</p><p class=\"headingAnchor\" id=\"H10395225\"><span class=\"h3\">Environmental cleaning</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CCHF virus can be inactivated by disinfectants including 1% sodium hypochlorite (household bleach), 70% alcohol, 2% glutaraldehyde, hydrogen peroxide, and peracetic acid, and the virus is susceptible to high temperature at 56&deg;C (133&deg;F) for 30 minutes or 60&deg;C for 15 minutes. Areas contaminated with CCHF virus can be disinfected with an approved hospital disinfectant or <span class=\"nowrap\">1/100</span> dilution of sodium hypochlorite [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/125\" class=\"abstract_t\">125</a>]. A <span class=\"nowrap\">1/10</span> dilution of sodium hypochlorite should be used for surfaces contaminated by blood and body fluid spills. Housekeeping staff should use personal protective equipment when cleaning.</p><p class=\"headingAnchor\" id=\"H538750304\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The mortality rate varies among countries and ranges from 2 to 80 percent [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/9,128-130\" class=\"abstract_t\">9,128-130</a>]. Mortality rates in endemic countries are around 4 to 20 percent [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/7,131-135\" class=\"abstract_t\">7,131-135</a>]. Most patients with Crimean-Congo hemorrhagic fever (CCHF) live in rural areas and may have limited or delayed access to healthcare facilities, which may be associated with adverse outcomes.</p><p>CCHF is a notifiable disease in Turkey and Iran, and both countries have active surveillance and detection systems. Between 2002 and 2015, 9787 cases were reported to the Ministry of Health in Turkey, with a mortality rate of 4.8 percent [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/133\" class=\"abstract_t\">133</a>]. The case-fatality rate is higher in nosocomial cases, probably due to high viral inoculum [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/122,136,137\" class=\"abstract_t\">122,136,137</a>].</p><p>Independent predictors of mortality include presence of hemorrhage (particularly gastrointestinal bleeding and hematuria) [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/138\" class=\"abstract_t\">138</a>], impaired consciousness [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/38,138\" class=\"abstract_t\">38,138</a>], central nervous system involvement, diarrhea [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/139\" class=\"abstract_t\">139</a>], splenomegaly [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/38\" class=\"abstract_t\">38</a>], thrombocytopenia [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/138\" class=\"abstract_t\">138</a>], leukocytosis, increased alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/139,140\" class=\"abstract_t\">139,140</a>], and decreased fibrinogen levels with a prolonged activated partial thromboplastin time [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/138-140\" class=\"abstract_t\">138-140</a>]. In addition, CCHF virus RNA level &gt;10<sup>7</sup> <span class=\"nowrap\">copies/mL</span> is an important indicator for mortality (positive predictive value 80 percent, sensitivity 89 percent, specificity 93 percent) [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/141,142\" class=\"abstract_t\">141,142</a>].</p><p>Severity scoring systems have been developed based on these factors [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/140,143,144\" class=\"abstract_t\">140,143,144</a>]; further prospective studies are needed.</p><p class=\"headingAnchor\" id=\"H538750322\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prevention consists of avoiding tick exposure and avoiding contact with animal bodily fluids. Issues related to prevention of nosocomial transmission are discussed above. (See <a href=\"#H10394923\" class=\"local\">'Infection control'</a> above.)</p><p>Residents of and travelers to endemic areas should be educated regarding personal protection measures to avoid tick bites [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/68,81\" class=\"abstract_t\">68,81</a>]. Wearing light-colored clothing allows easy detection of ticks, and tucking shirts into pants and pants into socks is helpful to minimize exposure. The use of a 20 to 30% N,N-diethyl-m-toluamide (DEET) repellant for skin provides some protection, and permethrin-treated clothes also help to prevent tick bites. Grassy areas should be avoided in warm seasons when ticks are most active. Ticks should not be handled with bare hands and should not be crushed or squeezed. Skin and clothes should be examined regularly for presence of ticks, and attached ticks should be removed with tweezers. Following tick removal, the skin should be cleaned with antiseptic. (See <a href=\"topic.htm?path=prevention-of-arthropod-and-insect-bites-repellents-and-other-measures\" class=\"medical medical_review\">&quot;Prevention of arthropod and insect bites: Repellents and other measures&quot;</a>.)</p><p>Control of Crimean-Congo hemorrhagic fever (CCHF) in animals is difficult. Restricted areas should be established for slaughtering. Acaricides are effective against ticks in livestock and should be applied to animals prior to entering slaughterhouses. All butchers and slaughters should be educated for preventive measures [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/145\" class=\"abstract_t\">145</a>]. Impervious protective clothes and gloves should be worn during slaughtering, butchering, and handling of animals [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/2\" class=\"abstract_t\">2</a>].</p><p>There is no approved vaccine for use in humans or animals. An inactivated suckling mouse brain&ndash;derived vaccine developed for CCHF is used in Bulgaria; it is given in three doses with a booster dose after five years and affords variable protection [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/146\" class=\"abstract_t\">146</a>]. Virus-neutralizing activity of this vaccine is low, and repeated doses are necessary to achieve adequate neutralizing antibody levels [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/147\" class=\"abstract_t\">147</a>]. Another vaccine based on CCHF virus glycoproteins is under development [<a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/148,149\" class=\"abstract_t\">148,149</a>]; further study is needed.</p><p class=\"headingAnchor\" id=\"H538750370\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Crimean-Congo hemorrhagic fever (CCHF) is a zoonotic disease transmitted by ticks and characterized by fever and hemorrhage. CCHF is endemic in parts of Africa, the Middle East, Asia, and southeastern Europe (<a href=\"image.htm?imageKey=ID%2F104847\" class=\"graphic graphic_figure graphicRef104847 \">figure 1</a>). In the Northern hemisphere, transmission of CCHF virus (CCHFV) is common between May and September; ticks survive most readily in relatively warm, dry habitats. (See <a href=\"#H538750190\" class=\"local\">'Introduction'</a> above and <a href=\"#H538750202\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>CCHFV is most commonly transmitted via ticks or direct contact with bodily fluids of infected animals; nosocomial transmission can also occur. Individuals in rural endemic areas working in animal husbandry are at highest risk for infection. The incubation period following tick bite is typically 1 to 3 days; the incubation period following contact with blood and body fluids is typically 3 to 7 days. (See <a href=\"#H538750214\" class=\"local\">'Transmission'</a> above and <a href=\"#H538750256\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical manifestations of CCHF include sudden onset of fever, headache, malaise, myalgia, sore throat, dizziness, conjunctivitis, photophobia, abdominal pain, nausea, and vomiting. In severe cases, hemorrhagic manifestations (petechiae, ecchymoses, epistaxis, and gum bleeding) are observed. Laboratory findings include thrombocytopenia, leukopenia, hyperbilirubinemia with elevated transaminases, and prolongation of prothrombin time and partial thromboplastin time. (See <a href=\"#H538750256\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of CCHF should be suspected in patients presenting with fever and bleeding who have relevant geographic and epidemiologic risk factors. Diagnostic tools include detection of CCHFV RNA by reverse-transcriptase polymerase chain reaction (RT-PCR) and serology. If available, RT-PCR is preferred. Specific immunoglobulin (Ig)M and IgG antibodies are detectable five days from the onset of symptoms. (See <a href=\"#H538750262\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Management of CCHF consists of supportive care; in severe cases, blood product replacement is warranted. Careful attention should be paid to fluid balance and electrolytes. Mechanical ventilation, hemodialysis, vasopressor, and inotropic agents may be needed. <a href=\"topic.htm?path=acetaminophen-paracetamol-drug-information\" class=\"drug drug_general\">Acetaminophen</a> may be used for fever and pain management; <a href=\"topic.htm?path=ibuprofen-drug-information\" class=\"drug drug_general\">ibuprofen</a> and <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> should be avoided as these agents can adversely affect normal clotting. (See <a href=\"#H538750280\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with CCHF should be managed in a healthcare center with appropriate facilities for management and prevention of infection. Infection control precautions (including standard, contact, and droplet precautions) must be implemented to prevent nosocomial transmission. (See <a href=\"#H10394923\" class=\"local\">'Infection control'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prevention of CCHF consists of avoiding tick exposure and avoiding contact with animal bodily fluids. (See <a href=\"#H538750322\" class=\"local\">'Prevention'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/1\" class=\"nounderline abstract_t\">van Eeden PJ, Joubert JR, van de Wal BW, et al. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part I. Clinical features. S Afr Med J 1985; 68:711.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/2\" class=\"nounderline abstract_t\">Whitehouse CA. Crimean-Congo hemorrhagic fever. Antiviral Res 2004; 64:145.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/3\" class=\"nounderline abstract_t\">Hoogstraal H. The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa. J Med Entomol 1979; 15:307.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/4\" class=\"nounderline abstract_t\">Simpson DI, Knight EM, Courtois G, et al. Congo virus: a hitherto undescribed virus occurring in Africa. I. Human isolations--clinical notes. East Afr Med J 1967; 44:86.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/5\" class=\"nounderline abstract_t\">Mertens M, Schmidt K, Ozkul A, Groschup MH. The impact of Crimean-Congo hemorrhagic fever virus on public health. Antiviral Res 2013; 98:248.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/6\" class=\"nounderline abstract_t\">Maltezou HC, Papa A. Crimean-Congo hemorrhagic fever: risk for emergence of new endemic foci in Europe? Travel Med Infect Dis 2010; 8:139.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/7\" class=\"nounderline abstract_t\">Leblebicioglu H, Ozaras R, Sunbul M. Crimean-Congo hemorrhagic fever: A neglected infectious disease with potential nosocomial infection threat. Am J Infect Control 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/8\" class=\"nounderline abstract_t\">Negredo A, de la Calle-Prieto F, Palencia-Herrej&oacute;n E, et al. Autochthonous Crimean-Congo Hemorrhagic Fever in Spain. N Engl J Med 2017; 377:154.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/9\" class=\"nounderline abstract_t\">Leblebicioglu H. Crimean-Congo haemorrhagic fever in Eurasia. Int J Antimicrob Agents 2010; 36 Suppl 1:S43.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/10\" class=\"nounderline abstract_t\">Papa A, Mirazimi A, K&ouml;ksal I, et al. Recent advances in research on Crimean-Congo hemorrhagic fever. J Clin Virol 2015; 64:137.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/11\" class=\"nounderline abstract_t\">Bajpai S, Nadkar MY. Crimean Congo hemorrhagic fever: requires vigilance and not panic. J Assoc Physicians India 2011; 59:164.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/12\" class=\"nounderline abstract_t\">Garc&iacute;a Rada A. First outbreak of Crimean-Congo haemorrhagic fever in western Europe kills one man in Spain. BMJ 2016; 354:i4891.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/13\" class=\"nounderline abstract_t\">Ince Y, Yasa C, Metin M, et al. Crimean-Congo hemorrhagic fever infections reported by ProMED. Int J Infect Dis 2014; 26:44.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/14\" class=\"nounderline abstract_t\">Yilmaz GR, Buzgan T, Irmak H, et al. The epidemiology of Crimean-Congo hemorrhagic fever in Turkey, 2002-2007. Int J Infect Dis 2009; 13:380.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/15\" class=\"nounderline abstract_t\">Sheikh AS, Sheikh AA, Sheikh NS, et al. Bi-annual surge of Crimean-Congo haemorrhagic fever (CCHF): a five-year experience. Int J Infect Dis 2005; 9:37.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/16\" class=\"nounderline abstract_t\">Aker S, Ak&#305;nc&#305; H, K&#305;l&#305;&ccedil;o&#287;lu C, Leblebicioglu H. The geographic distribution of cases of Crimean-Congo hemorrhagic fever: Kastamonu, Turkey. Ticks Tick Borne Dis 2015; 6:730.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/17\" class=\"nounderline abstract_t\">Gunaydin NS, Aydin K, Yilmaz G, et al. Crimean-Congo hemorrhagic fever cases in the eastern Black Sea region of Turkey: Demographic, geographic, climatic, and clinical characteristics. Turk J Med Sci 2010; 40:829.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/18\" class=\"nounderline abstract_t\">Sisman A. Epidemiologic features and risk factors of Crimean-Congo hemorrhagic fever in Samsun province, Turkey. J Epidemiol 2013; 23:95.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/19\" class=\"nounderline abstract_t\">Anagnostou V, Papa A. Evolution of Crimean-Congo Hemorrhagic Fever virus. Infect Genet Evol 2009; 9:948.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/20\" class=\"nounderline abstract_t\">Papa A, Dalla V, Papadimitriou E, et al. Emergence of Crimean-Congo haemorrhagic fever in Greece. Clin Microbiol Infect 2010; 16:843.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/21\" class=\"nounderline abstract_t\">Hoogstraal H. Changing patterns of tickborne diseases in modern society. Annu Rev Entomol 1981; 26:75.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/22\" class=\"nounderline abstract_t\">Gonzalez JP, Cornet JP, Wilson ML, Camicas JL. Crimean-Congo haemorrhagic fever virus replication in adult Hyalomma truncatum and Amblyomma variegatum ticks. Res Virol 1991; 142:483.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/23\" class=\"nounderline abstract_t\">Lauterbach R, Wells K, O'Hara RB, et al. Variable strength of forest stand attributes and weather conditions on the questing activity of Ixodes ricinus ticks over years in managed forests. PLoS One 2013; 8:e55365.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/24\" class=\"nounderline abstract_t\">Gray JS, Dautel H, Estrada-Pe&ntilde;a A, et al. Effects of climate change on ticks and tick-borne diseases in europe. Interdiscip Perspect Infect Dis 2009; 2009:593232.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/25\" class=\"nounderline abstract_t\">Sekercio&#287;lu CH. Guineafowl, ticks and Crimean-Congo hemorrhagic fever in Turkey: the perfect storm? Trends Parasitol 2013; 29:1.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/26\" class=\"nounderline abstract_t\">Estrada-Pe&ntilde;a A, Vatansever Z, Gargili A, Erg&ouml;nul O. The trend towards habitat fragmentation is the key factor driving the spread of Crimean-Congo haemorrhagic fever. Epidemiol Infect 2010; 138:1194.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/27\" class=\"nounderline abstract_t\">Estrada-Pe&ntilde;a A, Zatansever Z, Gargili A, et al. Modeling the spatial distribution of crimean-congo hemorrhagic fever outbreaks in Turkey. Vector Borne Zoonotic Dis 2007; 7:667.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/28\" class=\"nounderline abstract_t\">Estrada-Pe&ntilde;a A, Ayll&oacute;n N, de la Fuente J. Impact of climate trends on tick-borne pathogen transmission. Front Physiol 2012; 3:64.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/29\" class=\"nounderline abstract_t\">Purnak T, Selvi NA, Altundag K. Global warming may increase the incidence and geographic range of Crimean-Congo Hemorrhagic Fever. Med Hypotheses 2007; 68:924.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/30\" class=\"nounderline abstract_t\">Chisholm K, Dueger E, Fahmy NT, et al. Crimean-congo hemorrhagic fever virus in ticks from imported livestock, Egypt. Emerg Infect Dis 2012; 18:181.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/31\" class=\"nounderline abstract_t\">Jameson LJ, Ramadani N, Medlock JM. Possible drivers of Crimean-Congo hemorrhagic fever virus transmission in Kosova. Vector Borne Zoonotic Dis 2012; 12:753.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/32\" class=\"nounderline abstract_t\">Alavi-Naini R, Moghtaderi A, Koohpayeh HR, et al. Crimean-Congo hemorrhagic fever in Southeast of Iran. J Infect 2006; 52:378.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/33\" class=\"nounderline abstract_t\">Leblebicioglu H, Eroglu C, Erciyas-Yavuz K, et al. Role of migratory birds in spreading Crimean-Congo hemorrhagic fever, Turkey. Emerg Infect Dis 2014; 20:1331.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/34\" class=\"nounderline abstract_t\">Leblebicioglu H, Ozaras R, Erciyas-Yavuz K. Emergence of Crimean-Congo hemorrhagic fever. Trans R Soc Trop Med Hyg 2015; 109:676.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/35\" class=\"nounderline abstract_t\">Kilpatrick AM, Randolph SE. Drivers, dynamics, and control of emerging vector-borne zoonotic diseases. Lancet 2012; 380:1946.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/36\" class=\"nounderline abstract_t\">Gunduz A, Turkmen S, Turedi S, et al. Tick attachment sites. Wilderness Environ Med 2008; 19:4.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/37\" class=\"nounderline abstract_t\">Kar S, Dervis E, Ak&#305;n A, et al. Preferences of different tick species for human hosts in Turkey. Exp Appl Acarol 2013; 61:349.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/38\" class=\"nounderline abstract_t\">Bakir M, Ugurlu M, Dokuzoguz B, et al. Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: a multicentre study of clinical features and outcome measures. J Med Microbiol 2005; 54:385.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/39\" class=\"nounderline abstract_t\">Capua I. Crimean-Congo haemorrhagic fever in ostriches: A public health risk for countries of the European Union? Avian Pathol 1998; 27:117.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/40\" class=\"nounderline abstract_t\">Jamil B, Hasan RS, Sarwari AR, et al. Crimean-Congo hemorrhagic fever: experience at a tertiary care hospital in Karachi, Pakistan. Trans R Soc Trop Med Hyg 2005; 99:577.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/41\" class=\"nounderline abstract_t\">Gozalan A, Esen B, Fitzner J, et al. Crimean-Congo haemorrhagic fever cases in Turkey. Scand J Infect Dis 2007; 39:332.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/42\" class=\"nounderline abstract_t\">Gozel MG, Bakir M, Oztop AY, et al. Investigation of Crimean-Congo hemorrhagic fever virus transmission from patients to relatives: a prospective contact tracing study. Am J Trop Med Hyg 2014; 90:160.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/43\" class=\"nounderline abstract_t\">Izadi S, Salehi M, Holakouie-Naieni K, Chinikar S. The risk of transmission of Crimean-Congo hemorrhagic fever virus from human cases to first-degree relatives. Jpn J Infect Dis 2008; 61:494.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/44\" class=\"nounderline abstract_t\">Burney MI, Ghafoor A, Saleen M, et al. Nosocomial outbreak of viral hemorrhagic fever caused by Crimean Hemorrhagic fever-Congo virus in Pakistan, January 1976. Am J Trop Med Hyg 1980; 29:941.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/45\" class=\"nounderline abstract_t\">Joubert JR, King JB, Rossouw DJ, Cooper R. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part III. Clinical pathology and pathogenesis. S Afr Med J 1985; 68:722.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/46\" class=\"nounderline abstract_t\">Sunbul M, Leblebicioglu H, Fletcher TE, et al. Crimean-Congo haemorrhagic fever and secondary bacteraemia in Turkey. J Infect 2015; 71:597.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/47\" class=\"nounderline abstract_t\">Leblebicioglu H, Sunbul M, Guner R, et al. Healthcare-associated Crimean-Congo haemorrhagic fever in Turkey, 2002-2014: a multicentre retrospective cross-sectional study. Clin Microbiol Infect 2016; 22:387.e1.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/48\" class=\"nounderline abstract_t\">Guner R, Hasanoglu I, Tasyaran MA, et al. Is ribavirin prophylaxis effective for nosocomial transmission of Crimean-Congo hemorrhagic fever? Vector Borne Zoonotic Dis 2014; 14:601.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/49\" class=\"nounderline abstract_t\">Athar MN, Baqai HZ, Ahmad M, et al. Short report: Crimean-Congo hemorrhagic fever outbreak in Rawalpindi, Pakistan, February 2002. Am J Trop Med Hyg 2003; 69:284.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/50\" class=\"nounderline abstract_t\">van de Wal BW, Joubert JR, van Eeden PJ, King JB. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part IV. Preventive and prophylactic measures. S Afr Med J 1985; 68:729.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/51\" class=\"nounderline abstract_t\">Pshenichnaya NY, Nenadskaya SA. Probable Crimean-Congo hemorrhagic fever virus transmission occurred after aerosol-generating medical procedures in Russia: nosocomial cluster. Int J Infect Dis 2015; 33:120.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/52\" class=\"nounderline abstract_t\">Conger NG, Paolino KM, Osborn EC, et al. Health care response to CCHF in US soldier and nosocomial transmission to health care providers, Germany, 2009. Emerg Infect Dis 2015; 21:23.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/53\" class=\"nounderline abstract_t\">G&uuml;rb&uuml;z Y, Sencan I, Ozt&uuml;rk B, T&uuml;t&uuml;nc&uuml; E. A case of nosocomial transmission of Crimean-Congo hemorrhagic fever from patient to patient. Int J Infect Dis 2009; 13:e105.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/54\" class=\"nounderline abstract_t\">Gozel MG, Elaldi N, Engin A, et al. Favorable outcomes for both mother and baby are possible in pregnant women with Crimean-Congo hemorrhagic fever disease: a case series and literature review. Gynecol Obstet Invest 2014; 77:266.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/55\" class=\"nounderline abstract_t\">Ergonul O, Celikbas A, Yildirim U, et al. Pregnancy and Crimean-Congo haemorrhagic fever. Clin Microbiol Infect 2010; 16:647.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/56\" class=\"nounderline abstract_t\">Erbay A, Cevik MA, Onguru P, et al. Breastfeeding in Crimean-Congo haemorrhagic fever. Scand J Infect Dis 2008; 40:186.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/57\" class=\"nounderline abstract_t\">Ergonul O, Battal I. Potential sexual transmission of Crimean-Congo hemorrhagic fever infection. Jpn J Infect Dis 2014; 67:137.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/58\" class=\"nounderline abstract_t\">Pshenichnaya NY, Sydenko IS, Klinovaya EP, et al. Possible sexual transmission of Crimean-Congo hemorrhagic fever. Int J Infect Dis 2016; 45:109.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/59\" class=\"nounderline abstract_t\">Aksoy HZ, Yilmaz G, Aksoy F, Koksal I. Crimean-Congo haemorrhagic fever presenting as epididymo-orchitis. J Clin Virol 2010; 48:282.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/60\" class=\"nounderline abstract_t\">Bodur H, Akinci E, Ong&uuml;r&uuml; P, et al. Detection of Crimean-Congo hemorrhagic fever virus genome in saliva and urine. Int J Infect Dis 2010; 14:e247.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/61\" class=\"nounderline abstract_t\">Thomas S, Thomson G, Dowall S, et al. Review of Crimean Congo hemorrhagic fever infection in Kosova in 2008 and 2009: prolonged viremias and virus detected in urine by PCR. Vector Borne Zoonotic Dis 2012; 12:800.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/62\" class=\"nounderline abstract_t\">Atkinson B, Latham J, Chamberlain J, et al. Sequencing and phylogenetic characterisation of a fatal Crimean - Congo haemorrhagic fever case imported into the United Kingdom, October 2012. Euro Surveill 2012; 17.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/63\" class=\"nounderline abstract_t\">Lumley S, Atkinson B, Dowall S, et al. Non-fatal case of Crimean-Congo haemorrhagic fever imported into the United Kingdom (ex Bulgaria), June 2014. Euro Surveill 2014; 19.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/64\" class=\"nounderline abstract_t\">Tall A, Sall AA, Faye O, et al. [Two cases of Crimean-Congo haemorrhagic fever (CCHF) in two tourists in Senegal in 2004]. Bull Soc Pathol Exot 2009; 102:159.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/65\" class=\"nounderline abstract_t\">Schwarz TF, Nsanze H, Ameen AM. Clinical features of Crimean-Congo haemorrhagic fever in the United Arab Emirates. Infection 1997; 25:364.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/66\" class=\"nounderline abstract_t\">Yilmaz GR, Buzgan T, Torunoglu MA, et al. A preliminary report on Crimean-Congo haemorrhagic fever in Turkey, March - June 2008. Euro Surveill 2008; 13.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/67\" class=\"nounderline abstract_t\">Beeching NJ, Fletcher TE, Hill DR, Thomson GL. Travellers and viral haemorrhagic fevers: what are the risks? Int J Antimicrob Agents 2010; 36 Suppl 1:S26.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/68\" class=\"nounderline abstract_t\">Leblebicioglu H, Ozaras R, Fletcher TE, et al. Crimean-Congo haemorrhagic fever in travellers: A systematic review. Travel Med Infect Dis 2016; 14:73.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/69\" class=\"nounderline abstract_t\">Bodur H, Akinci E, Ascioglu S, et al. Subclinical infections with Crimean-Congo hemorrhagic fever virus, Turkey. Emerg Infect Dis 2012; 18:640.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/70\" class=\"nounderline abstract_t\">Gunes T, Engin A, Poyraz O, et al. Crimean-Congo hemorrhagic fever virus in high-risk population, Turkey. Emerg Infect Dis 2009; 15:461.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/71\" class=\"nounderline abstract_t\">Koksal I, Yilmaz G, Aksoy F, et al. The seroprevalance of Crimean-Congo haemorrhagic fever in people living in the same environment with Crimean-Congo haemorrhagic fever patients in an endemic region in Turkey. Epidemiol Infect 2014; 142:239.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/72\" class=\"nounderline abstract_t\">Christova I, Gladnishka T, Taseva E, et al. Seroprevalence of Crimean-Congo hemorrhagic fever virus, Bulgaria. Emerg Infect Dis 2013; 19:177.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/73\" class=\"nounderline abstract_t\">Zehender G, Ebranati E, Shkjezi R, et al. Bayesian phylogeography of Crimean-Congo hemorrhagic fever virus in Europe. PLoS One 2013; 8:e79663.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/74\" class=\"nounderline abstract_t\">Chinikar S, Shah-Hosseini N, Bouzari S, et al. New circulating genomic variant of Crimean-Congo hemorrhagic fever virus in Iran. Arch Virol 2013; 158:1085.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/75\" class=\"nounderline abstract_t\">Deyde VM, Khristova ML, Rollin PE, et al. Crimean-Congo hemorrhagic fever virus genomics and global diversity. J Virol 2006; 80:8834.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/76\" class=\"nounderline abstract_t\">Burt FJ, Swanepoel R. Molecular epidemiology of African and Asian Crimean-Congo haemorrhagic fever isolates. Epidemiol Infect 2005; 133:659.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/77\" class=\"nounderline abstract_t\">Mild M, Simon M, Albert J, Mirazimi A. Towards an understanding of the migration of Crimean-Congo hemorrhagic fever virus. J Gen Virol 2010; 91:199.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/78\" class=\"nounderline abstract_t\">Papa A, Christova I, Papadimitriou E, Antoniadis A. Crimean-Congo hemorrhagic fever in Bulgaria. Emerg Infect Dis 2004; 10:1465.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/79\" class=\"nounderline abstract_t\">Fajs L, Humolli I, Saksida A, et al. Prevalence of Crimean-Congo hemorrhagic fever virus in healthy population, livestock and ticks in Kosovo. PLoS One 2014; 9:e110982.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/80\" class=\"nounderline abstract_t\">Mahzounieh M, Dincer E, Faraji A, et al. Relationship between Crimean-Congo hemorrhagic fever virus strains circulating in Iran and Turkey: possibilities for transborder transmission. Vector Borne Zoonotic Dis 2012; 12:782.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/81\" class=\"nounderline abstract_t\">Vorou R, Pierroutsakos IN, Maltezou HC. Crimean-Congo hemorrhagic fever. Curr Opin Infect Dis 2007; 20:495.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/82\" class=\"nounderline abstract_t\">Nabeth P, Thior M, Faye O, Simon F. Human Crimean-Congo hemorrhagic fever, S&eacute;n&eacute;gal. Emerg Infect Dis 2004; 10:1881.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/83\" class=\"nounderline abstract_t\">Naderi HR, Sheybani F, Bojdi A, et al. Fatal nosocomial spread of Crimean-Congo hemorrhagic fever with very short incubation period. Am J Trop Med Hyg 2013; 88:469.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/84\" class=\"nounderline abstract_t\">Elaldi N, Bodur H, Ascioglu S, et al. Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. J Infect 2009; 58:238.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/85\" class=\"nounderline abstract_t\">Swanepoel R, Shepherd AJ, Leman PA, et al. Epidemiologic and clinical features of Crimean-Congo hemorrhagic fever in southern Africa. Am J Trop Med Hyg 1987; 36:120.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/86\" class=\"nounderline abstract_t\">Dogan OT, Engin A, Salk I, et al. Evaluation of respiratory findings in Crimean-Congo hemorrhagic fever. Southeast Asian J Trop Med Public Health 2011; 42:1100.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/87\" class=\"nounderline abstract_t\">Engin A, Erdogan H, Ozec AV, et al. Ocular findings in patients with Crimean-Congo hemorrhagic fever. Am J Ophthalmol 2009; 147:634.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/88\" class=\"nounderline abstract_t\">Mardani M, Keshtkar-Jahromi M. Crimean-Congo hemorrhagic fever. Arch Iran Med 2007; 10:204.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/89\" class=\"nounderline abstract_t\">Ak&#305;nc&#305; E, Bodur H, Leblebicioglu H. Pathogenesis of Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis 2013; 13:429.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/90\" class=\"nounderline abstract_t\">Bodur H, Akinci E, Ong&uuml;r&uuml; P, et al. Evidence of vascular endothelial damage in Crimean-Congo hemorrhagic fever. Int J Infect Dis 2010; 14:e704.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/91\" class=\"nounderline abstract_t\">Bente DA, Forrester NL, Watts DM, et al. Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res 2013; 100:159.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/92\" class=\"nounderline abstract_t\">Chen JP, Cosgriff TM. Hemorrhagic fever virus-induced changes in hemostasis and vascular biology. Blood Coagul Fibrinolysis 2000; 11:461.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/93\" class=\"nounderline abstract_t\">Papa A, Bino S, Velo E, et al. Cytokine levels in Crimean-Congo hemorrhagic fever. J Clin Virol 2006; 36:272.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/94\" class=\"nounderline abstract_t\">Onguru P, Dagdas S, Bodur H, et al. Coagulopathy parameters in patients with Crimean-Congo hemorrhagic fever and its relation with mortality. J Clin Lab Anal 2010; 24:163.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/95\" class=\"nounderline abstract_t\">Yapar M, Aydogan H, Pahsa A, et al. Rapid and quantitative detection of Crimean-Congo hemorrhagic fever virus by one-step real-time reverse transcriptase-PCR. Jpn J Infect Dis 2005; 58:358.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/96\" class=\"nounderline abstract_t\">Duh D, Saksida A, Petrovec M, et al. Novel one-step real-time RT-PCR assay for rapid and specific diagnosis of Crimean-Congo hemorrhagic fever encountered in the Balkans. J Virol Methods 2006; 133:175.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/97\" class=\"nounderline abstract_t\">Atkinson B, Chamberlain J, Logue CH, et al. Development of a real-time RT-PCR assay for the detection of Crimean-Congo hemorrhagic fever virus. Vector Borne Zoonotic Dis 2012; 12:786.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/98\" class=\"nounderline abstract_t\">Uyar Y, Carhan A, Albayrak N, Alta&#351; AB. [Evaluation of PCR and ELISA-IgM results in the laboratory diagnosis of Crimean-Congo haemorrhagic fever cases in 2008 in Turkey]. Mikrobiyol Bul 2010; 44:57.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/99\" class=\"nounderline abstract_t\">Watts DM, Ussery MA, Nash D, Peters CJ. Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. Am J Trop Med Hyg 1989; 41:581.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/100\" class=\"nounderline abstract_t\">Tignor GH, Hanham CA. Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection. Antiviral Res 1993; 22:309.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/101\" class=\"nounderline abstract_t\">Bente DA, Alimonti JB, Shieh WJ, et al. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J Virol 2010; 84:11089.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/102\" class=\"nounderline abstract_t\">Oestereich L, Rieger T, Neumann M, et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl Trop Dis 2014; 8:e2804.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/103\" class=\"nounderline abstract_t\">Bodur H, Erbay A, Ak&#305;nc&#305; E, et al. Effect of oral ribavirin treatment on the viral load and disease progression in Crimean-Congo hemorrhagic fever. Int J Infect Dis 2011; 15:e44.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/104\" class=\"nounderline abstract_t\">Cevik MA, Elaldi N, Akinci E, et al. A preliminary study to evaluate the effect of intravenous ribavirin treatment on survival rates in Crimean-Congo hemorrhagic fever. J Infect 2008; 57:350.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/105\" class=\"nounderline abstract_t\">Koksal I, Yilmaz G, Aksoy F, et al. The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey. J Clin Virol 2010; 47:65.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/106\" class=\"nounderline abstract_t\">Ozkurt Z, Kiki I, Erol S, et al. Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect 2006; 52:207.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/107\" class=\"nounderline abstract_t\">Tasdelen Fisgin N, Ergonul O, Doganci L, Tulek N. The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising. Eur J Clin Microbiol Infect Dis 2009; 28:929.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/108\" class=\"nounderline abstract_t\">Soares-Weiser K, Thomas S, Thomson G, Garner P. Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis. BMC Infect Dis 2010; 10:207.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/109\" class=\"nounderline abstract_t\">Ceylan B, Cal&#305;ca A, Ak O, et al. Ribavirin is not effective against Crimean-Congo hemorrhagic fever: observations from the Turkish experience. Int J Infect Dis 2013; 17:e799.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/110\" class=\"nounderline abstract_t\">Mardani M, Jahromi MK, Naieni KH, Zeinali M. The efficacy of oral ribavirin in the treatment of crimean-congo hemorrhagic fever in Iran. Clin Infect Dis 2003; 36:1613.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/111\" class=\"nounderline abstract_t\">Ascioglu S, Leblebicioglu H, Vahaboglu H, Chan KA. Ribavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66:1215.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/112\" class=\"nounderline abstract_t\">Ceylan B, Turhan V. The efficacy of ribavirin in Crimean-Congo hemorrhagic fever--randomized trials are urgently needed. Int J Infect Dis 2014; 29:297.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/113\" class=\"nounderline abstract_t\">Leblebicioglu H, Bodur H, Dokuzoguz B, et al. Case management and supportive treatment for patients with Crimean-Congo hemorrhagic fever. Vector Borne Zoonotic Dis 2012; 12:805.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/114\" class=\"nounderline abstract_t\">Sharifi-Mood B, Alavi-Naini R, Metanat M, et al. Efficacy of high-dose methylprednisolone in patients with Crimean-Congo haemorrhagic fever and severe thrombocytopenia. Trop Doct 2013; 43:49.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/115\" class=\"nounderline abstract_t\">Kurnaz F, Metan G, Coskun R, et al. A case of Crimean-Congo haemorrhagic fever successfully treated with therapeutic plasma exchange and ribavirin. Trop Doct 2011; 41:181.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/116\" class=\"nounderline abstract_t\">Me&ccedil;o BC, Memiko&#287;lu O, Ilhan O, et al. Double filtration plasmapheresis for a case of Crimean-Congo hemorrhagic fever. Transfus Apher Sci 2013; 48:331.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/117\" class=\"nounderline abstract_t\">Kubar A, Haciomeroglu M, Ozkul A, et al. Prompt administration of Crimean-Congo hemorrhagic fever (CCHF) virus hyperimmunoglobulin in patients diagnosed with CCHF and viral load monitorization by reverse transcriptase-PCR. Jpn J Infect Dis 2011; 64:439.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/118\" class=\"nounderline abstract_t\">British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br J Haematol 2003; 122:10.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/119\" class=\"nounderline abstract_t\">Gozel MG, Dokmetas I, Oztop AY, et al. Recommended precaution procedures protect healthcare workers from Crimean-Congo hemorrhagic fever virus. Int J Infect Dis 2013; 17:e1046.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/120\" class=\"nounderline abstract_t\">Fletcher TE, Brooks TJ, Beeching NJ. Ebola and other viral haemorrhagic fevers. BMJ 2014; 349:g5079.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/121\" class=\"nounderline abstract_t\">Smego RA Jr, Sarwari AR, Siddiqui AR. Crimean-Congo hemorrhagic fever: prevention and control limitations in a resource-poor country. Clin Infect Dis 2004; 38:1731.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/122\" class=\"nounderline abstract_t\">Athar MN, Khalid MA, Ahmad AM, et al. Crimean-Congo hemorrhagic fever outbreak in Rawalpindi, Pakistan, February 2002: contact tracing and risk assessment. Am J Trop Med Hyg 2005; 72:471.</a></li><li class=\"breakAll\">World Health Organization. Clinical management of patients with viral haemorrhagic fever: A pocket guide for front-line health workers, February 2016. WHO, Geneva 2016. http://apps.who.int/iris/bitstream/10665/205570/1/9789241549608_eng.pdf?ua=1 (Accessed on May 02, 2016).</li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/124\" class=\"nounderline abstract_t\">Leblebicioglu H, Sunbul M, Bodur H, et al. Discharge criteria for Crimean-Congo haemorrhagic fever in endemic areas. J Infect 2016; 72:500.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/125\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Update: management of patients with suspected viral hemorrhagic fever--United States. MMWR Morb Mortal Wkly Rep 1995; 44:475.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/126\" class=\"nounderline abstract_t\">Bangash SA, Khan EA. Treatment and prophylaxis with ribavirin for Crimean-Congo Hemorrhagic Fever--is it effective? J Pak Med Assoc 2003; 53:39.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/127\" class=\"nounderline abstract_t\">Celikbas AK, Dokuzo&#287;uz B, Baykam N, et al. Crimean-Congo hemorrhagic fever among health care workers, Turkey. Emerg Infect Dis 2014; 20:477.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/128\" class=\"nounderline abstract_t\">Sharifi-Mood B, Mardani M, Keshtkar-Jahromi M, et al. Clinical and epidemiologic features of Crimean-Congo hemorrhagic fever among children and adolescents from southeastern Iran. Pediatr Infect Dis J 2008; 27:561.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/129\" class=\"nounderline abstract_t\">Tezer H, Sucakli IA, Sayli TR, et al. Crimean-Congo hemorrhagic fever in children. J Clin Virol 2010; 48:184.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/130\" class=\"nounderline abstract_t\">Dilber E, Cakir M, Acar EA, et al. Crimean-Congo haemorrhagic fever among children in north-eastern Turkey. Ann Trop Paediatr 2009; 29:23.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/131\" class=\"nounderline abstract_t\">Dreshaj S, Ahmeti S, Ramadani N, et al. Current situation of Crimean-Congo hemorrhagic fever in Southeastern Europe and neighboring countries: a public health risk for the European Union? Travel Med Infect Dis 2016; 14:81.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/132\" class=\"nounderline abstract_t\">Keshtkar-Jahromi M, Sajadi MM, Ansari H, et al. Crimean-Congo hemorrhagic fever in Iran. Antiviral Res 2013; 100:20.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/133\" class=\"nounderline abstract_t\">Leblebicioglu H, Ozaras R, Irmak H, Sencan I. Crimean-Congo hemorrhagic fever in Turkey: Current status and future challenges. Antiviral Res 2016; 126:21.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/134\" class=\"nounderline abstract_t\">Nurmakhanov T, Sansyzbaev Y, Atshabar B, et al. Crimean-Congo haemorrhagic fever virus in Kazakhstan (1948-2013). Int J Infect Dis 2015; 38:19.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/135\" class=\"nounderline abstract_t\">Shaikh MA, Safder S, Bhatty SA. Crimean-Congo Haemorrhagic Fever: Breaking the chain of transmission. J Pak Med Assoc 2015; 65:576.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/136\" class=\"nounderline abstract_t\">Altaf A, Luby S, Ahmed AJ, et al. Outbreak of Crimean-Congo haemorrhagic fever in Quetta, Pakistan: contact tracing and risk assessment. Trop Med Int Health 1998; 3:878.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/137\" class=\"nounderline abstract_t\">Chinikar S, Ghiasi SM, Hewson R, et al. Crimean-Congo hemorrhagic fever in Iran and neighboring countries. J Clin Virol 2010; 47:110.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/138\" class=\"nounderline abstract_t\">Cevik MA, Erbay A, Bodur H, et al. Clinical and laboratory features of Crimean-Congo hemorrhagic fever: predictors of fatality. Int J Infect Dis 2008; 12:374.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/139\" class=\"nounderline abstract_t\">Hatipoglu CA, Bulut C, Yetkin MA, et al. Evaluation of clinical and laboratory predictors of fatality in patients with Crimean-Congo haemorrhagic fever in a tertiary care hospital in Turkey. Scand J Infect Dis 2010; 42:516.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/140\" class=\"nounderline abstract_t\">Swanepoel R, Gill DE, Shepherd AJ, et al. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis 1989; 11 Suppl 4:S794.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/141\" class=\"nounderline abstract_t\">Cevik MA, Erbay A, Bodur H, et al. Viral load as a predictor of outcome in Crimean-Congo hemorrhagic fever. Clin Infect Dis 2007; 45:e96.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/142\" class=\"nounderline abstract_t\">Duh D, Saksida A, Petrovec M, et al. Viral load as predictor of Crimean-Congo hemorrhagic fever outcome. Emerg Infect Dis 2007; 13:1769.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/143\" class=\"nounderline abstract_t\">Dokuzoguz B, Celikbas AK, G&ouml;k &#350;E, et al. Severity scoring index for Crimean-Congo hemorrhagic fever and the impact of ribavirin and corticosteroids on fatality. Clin Infect Dis 2013; 57:1270.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/144\" class=\"nounderline abstract_t\">Bak&#305;r M, G&ouml;zel MG, K&ouml;ksal I, et al. Validation of a severity grading score (SGS) system for predicting the course of disease and mortality in patients with Crimean-Congo hemorrhagic fever (CCHF). Eur J Clin Microbiol Infect Dis 2015; 34:325.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/145\" class=\"nounderline abstract_t\">Leblebicioglu H, Sunbul M, Memish ZA, et al. Consensus report: Preventive measures for Crimean-Congo Hemorrhagic Fever during Eid-al-Adha festival. Int J Infect Dis 2015; 38:9.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/146\" class=\"nounderline abstract_t\">Papa A, Papadimitriou E, Christova I. The Bulgarian vaccine Crimean-Congo haemorrhagic fever virus strain. Scand J Infect Dis 2011; 43:225.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/147\" class=\"nounderline abstract_t\">Mousavi-Jazi M, Karlberg H, Papa A, et al. Healthy individuals' immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine. Vaccine 2012; 30:6225.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/148\" class=\"nounderline abstract_t\">Buttigieg KR, Dowall SD, Findlay-Wilson S, et al. A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model. PLoS One 2014; 9:e91516.</a></li><li><a href=\"https://www.uptodate.com/contents/crimean-congo-hemorrhagic-fever/abstract/149\" class=\"nounderline abstract_t\">Dowall SD, Buttigieg KR, Findlay-Wilson SJ, et al. A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease. Hum Vaccin Immunother 2016; 12:519.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 102363 Version 7.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H538750370\"><span>SUMMARY</span></a></li><li><a href=\"#H538750190\" id=\"outline-link-H538750190\">INTRODUCTION</a></li><li><a href=\"#H538750202\" id=\"outline-link-H538750202\">EPIDEMIOLOGY</a><ul><li><a href=\"#H10384496\" id=\"outline-link-H10384496\">Geography and season</a><ul><li><a href=\"#H538750208\" id=\"outline-link-H538750208\">- Ticks</a></li><li><a href=\"#H10384935\" id=\"outline-link-H10384935\">- Disease emergence</a></li></ul></li><li><a href=\"#H538750214\" id=\"outline-link-H538750214\">Transmission</a></li><li><a href=\"#H538750220\" id=\"outline-link-H538750220\">Risk groups</a></li></ul></li><li><a href=\"#H8904604\" id=\"outline-link-H8904604\">VIROLOGY</a></li><li><a href=\"#H538750256\" id=\"outline-link-H538750256\">CLINICAL MANIFESTATIONS</a></li><li><a href=\"#H538750262\" id=\"outline-link-H538750262\">DIAGNOSIS</a></li><li><a href=\"#H538750274\" id=\"outline-link-H538750274\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H538750280\" id=\"outline-link-H538750280\">TREATMENT</a><ul><li><a href=\"#H538750286\" id=\"outline-link-H538750286\">Supportive care</a></li><li><a href=\"#H10394923\" id=\"outline-link-H10394923\">Infection control</a><ul><li><a href=\"#H10395304\" id=\"outline-link-H10395304\">- Precautions</a></li><li><a href=\"#H10395078\" id=\"outline-link-H10395078\">- Postexposure management</a></li><li><a href=\"#H10395225\" id=\"outline-link-H10395225\">- Environmental cleaning</a></li></ul></li></ul></li><li><a href=\"#H538750304\" id=\"outline-link-H538750304\">PROGNOSIS</a></li><li><a href=\"#H538750322\" id=\"outline-link-H538750322\">PREVENTION</a></li><li><a href=\"#H538750370\" id=\"outline-link-H538750370\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/102363|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/104847\" class=\"graphic graphic_figure\">- Crimean-Congo distribution map</a></li><li><a href=\"image.htm?imageKey=ID/104846\" class=\"graphic graphic_figure\">- Two-host ixodid tick life cycle</a></li></ul></li><li><div id=\"ID/102363|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/104939\" class=\"graphic graphic_picture\">- CCHF petechiae</a></li><li><a href=\"image.htm?imageKey=ID/104940\" class=\"graphic graphic_picture\">- CCHF ecchymosis tick</a></li><li><a href=\"image.htm?imageKey=ID/104941\" class=\"graphic graphic_picture\">- CCHF ecchymosis injection</a></li><li><a href=\"image.htm?imageKey=ID/104942\" class=\"graphic graphic_picture\">- CCHF gum bleeding</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-features-diagnosis-and-management-of-relapsing-fever\" class=\"medical medical_review\">Clinical features, diagnosis, and management of relapsing fever</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-ebola-virus-disease\" class=\"medical medical_review\">Clinical manifestations and diagnosis of Ebola virus disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-q-fever\" class=\"medical medical_review\">Clinical manifestations and diagnosis of Q fever</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-natural-history-of-hepatitis-b-virus-infection\" class=\"medical medical_review\">Clinical manifestations and natural history of hepatitis B virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-malaria-in-nonpregnant-adults-and-children\" class=\"medical medical_review\">Clinical manifestations of malaria in nonpregnant adults and children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-meningococcal-infection\" class=\"medical medical_review\">Clinical manifestations of meningococcal infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-treatment-of-brucellosis\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and treatment of brucellosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-acute-myeloid-leukemia\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dengue-virus-infection-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Dengue virus infection: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-evaluation-of-chronic-hepatitis-c-virus-infection\" class=\"medical medical_review\">Diagnosis and evaluation of chronic hepatitis C virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-malaria\" class=\"medical medical_review\">Diagnosis of malaria</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-meningococcal-infection\" class=\"medical medical_review\">Diagnosis of meningococcal infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-microbiology-clinical-manifestations-and-diagnosis-of-leptospirosis\" class=\"medical medical_review\">Epidemiology, microbiology, clinical manifestations, and diagnosis of leptospirosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatitis-a-virus-infection-in-adults-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Hepatitis A virus infection in adults: Epidemiology, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatitis-b-virus-screening-and-diagnosis\" class=\"medical medical_review\">Hepatitis B virus: Screening and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immune-thrombocytopenia-itp-in-adults-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Immune thrombocytopenia (ITP) in adults: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection\" class=\"medical medical_review\">Infection prevention: Precautions for preventing transmission of infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lassa-fever\" class=\"medical medical_review\">Lassa fever</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=marburg-virus\" class=\"medical medical_review\">Marburg virus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=other-spotted-fever-group-rickettsial-infections\" class=\"medical medical_review\">Other spotted fever group rickettsial infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-arthropod-and-insect-bites-repellents-and-other-measures\" class=\"medical medical_review\">Prevention of arthropod and insect bites: Repellents and other measures</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=scrub-typhus-clinical-features-and-diagnosis\" class=\"medical medical_review\">Scrub typhus: Clinical features and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=yellow-fever\" class=\"medical medical_review\">Yellow fever</a></li></ul></div></div>","javascript":null}